Literature DB >> 24337217

Sex differences in the incidence of chronic myeloid leukemia.

Tomas Radivoyevitch1, Gradimir M Jankovic, Ramon V Tiu, Yogen Saunthararajah, Robert C Jackson, Lynn R Hlatky, Robert Peter Gale, Rainer K Sachs.   

Abstract

The incidence of chronic myeloid leukemia (CML), which is caused by BCR/ABL chimeric oncogene formation in a pluripotent hematopoietic stem cell (HSC), increases with age and exposure to ionizing radiation. CML is a comparatively well-characterized neoplasm, important for its own sake and useful for insights into other neoplasms. Here, Surveillance, Epidemiology and End Results (SEER) CML data are analyzed after considering possible misclassification of chronic myelo-monocytic leukemia as CML. For people older than 25 years, plots of male and female CML log incidences versus age at diagnosis are approximately parallel straight lines with males either above or to the left of females. This is consistent with males having a higher risk of developing CML or a shorter latency from initiation to diagnosis of CML. These distinct mechanisms cannot be distinguished using SEER data alone. Therefore, CML risks among male and female Japanese A-bomb survivors are also analyzed. The present analyses suggest that sex differences in CML incidence more likely result from differences in risk than in latency. The simplest but not the sole interpretation of this is that males have more target cells at risk to develop CML. Comprehensive mathematical models of CML could lead to a better understanding of the role of HSCs in CML and other preleukemias that can progress to acute leukemia.

Entities:  

Mesh:

Year:  2013        PMID: 24337217      PMCID: PMC3943788          DOI: 10.1007/s00411-013-0507-4

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  17 in total

1.  The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias.

Authors:  S Kozubek; E Lukásová; A Marecková; M Skalníková; M Kozubek; E Bártová; V Kroha; E Krahulcová; J Slotová
Journal:  Chromosoma       Date:  1999-12       Impact factor: 4.316

2.  Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions.

Authors:  T Radivoyevitch; S Kozubek; R K Sachs
Journal:  Radiat Environ Biophys       Date:  2001-03       Impact factor: 1.925

3.  Leukemia, lymphoma, and multiple myeloma after pelvic radiotherapy for benign disease.

Authors:  P D Inskip; R A Kleinerman; M Stovall; D L Cookfair; O Hadjimichael; W C Moloney; R R Monson; W D Thompson; J Wactawski-Wende; J K Wagoner
Journal:  Radiat Res       Date:  1993-07       Impact factor: 2.841

Review 4.  Multistage carcinogenesis and the incidence of human cancer.

Authors:  Suresh H Moolgavkar; E Georg Luebeck
Journal:  Genes Chromosomes Cancer       Date:  2003-12       Impact factor: 5.006

Review 5.  Systems biological and mechanistic modelling of radiation-induced cancer.

Authors:  M P Little; W F Heidenreich; S H Moolgavkar; H Schöllnberger; D C Thomas
Journal:  Radiat Environ Biophys       Date:  2007-12-21       Impact factor: 1.925

6.  International study of factors affecting human chromosome translocations.

Authors:  Alice J Sigurdson; Mina Ha; Michael Hauptmann; Parveen Bhatti; Radim J Sram; Olena Beskid; E Janet Tawn; Caroline A Whitehouse; Carita Lindholm; Mimako Nakano; Yoshiaki Kodama; Nori Nakamura; Irena Vorobtsova; Ursula Oestreicher; Günther Stephan; Lee C Yong; Manfred Bauchinger; Ernst Schmid; Hai Won Chung; Firouz Darroudi; Laurence Roy; Phillipe Voisin; Joan F Barquinero; Gordon Livingston; David Blakey; Isamu Hayata; Wei Zhang; Chunyan Wang; L Michelle Bennett; L Gayle Littlefield; Alan A Edwards; Ruth A Kleinerman; James D Tucker
Journal:  Mutat Res       Date:  2008-02-02       Impact factor: 2.433

7.  Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.

Authors:  D L Preston; S Kusumi; M Tomonaga; S Izumi; E Ron; A Kuramoto; N Kamada; H Dohy; T Matsuo; T ] Matsui T [corrected to Matsuo
Journal:  Radiat Res       Date:  1994-02       Impact factor: 2.841

8.  Comprehensive mapping of long-range interactions reveals folding principles of the human genome.

Authors:  Erez Lieberman-Aiden; Nynke L van Berkum; Louise Williams; Maxim Imakaev; Tobias Ragoczy; Agnes Telling; Ido Amit; Bryan R Lajoie; Peter J Sabo; Michael O Dorschner; Richard Sandstrom; Bradley Bernstein; M A Bender; Mark Groudine; Andreas Gnirke; John Stamatoyannopoulos; Leonid A Mirny; Eric S Lander; Job Dekker
Journal:  Science       Date:  2009-10-09       Impact factor: 47.728

9.  Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.

Authors:  Yiming Chen; Haijun Wang; Hagop Kantarjian; Jorge Cortes
Journal:  Leuk Lymphoma       Date:  2012-12-05

Review 10.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

View more
  9 in total

1.  Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same.

Authors:  R P Gale; J F Apperley
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 2.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

3.  Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

Authors:  T Radivoyevitch; R K Sachs; R P Gale; R J Molenaar; D J Brenner; B T Hill; M E Kalaycio; H E Carraway; S Mukherjee; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2015-09-22       Impact factor: 11.528

Review 4.  Sexual dimorphism in solid and hematological malignancies.

Authors:  Isabel Ben-Batalla; María Elena Vargas-Delgado; Lara Meier; Sonja Loges
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

Review 5.  Chronic myeloid leukemia stem cells.

Authors:  Mohammad Houshmand; Giorgia Simonetti; Paola Circosta; Valentina Gaidano; Alessandro Cignetti; Giovanni Martinelli; Giuseppe Saglio; Robert Peter Gale
Journal:  Leukemia       Date:  2019-05-24       Impact factor: 11.528

Review 6.  Prospects for achieving treatment-free remission in chronic myeloid leukaemia.

Authors:  Giuseppe Saglio; Robert P Gale
Journal:  Br J Haematol       Date:  2020-02-14       Impact factor: 6.998

Review 7.  Natural Killer Cell-Mediated Immunotherapy for Leukemia.

Authors:  Michaela Allison; Joel Mathews; Taylor Gilliland; Stephen O Mathew
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

8.  CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells.

Authors:  Xiao-Fang Wei; You-Fan Feng; Qiao-Lin Chen; Qi-Ke Zhang
Journal:  Cancer Cell Int       Date:  2018-07-09       Impact factor: 5.722

9.  Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population.

Authors:  Natasha Monte; Karla B C C Pantoja; Juliana C G Rodrigues; Darlen C de Carvalho; Tereza C B Azevedo; Esdras E B Pereira; Paulo P de Assumpção; Sidney E B Dos Santos; Marianne R Fernandes; Ney P C Dos Santos
Journal:  Mol Genet Genomic Med       Date:  2021-05-29       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.